MedTrace Logo

Cryptococcal Optimal ART Timing Trial

NCT01075152 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 177

Last updated 2020-06-09

Study results available
· View outcomes & findings →

Summary

The Cryptococcal Optimal ART Timing (COAT) trial seeks to determine after cryptococcal meningitis (CM) whether early initiation of antiretroviral therapy (ART) prior to hospital discharge results in superior survival compared to standard initiation of ART started as an outpatient.

Conditions

  • Cryptococcal Meningitis
  • HIV Infections
  • AIDS

Interventions

DRUG

efavirenz

Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.

BIOLOGICAL

nucleoside

Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.

Sponsors & Collaborators

  • Mbarara University of Science and Technology

    collaborator OTHER

  • Makerere University

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • University of Cape Town

    collaborator OTHER

  • University of Minnesota

    lead OTHER

Principal Investigators

  • David R Boulware, MD, MPH · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2012-10-31
Completion
2013-03-31

Countries

  • South Africa
  • Uganda

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01075152 on ClinicalTrials.gov